Jonathan M. Meyer, MD, DLFAPA

home / authors / jonathan-m-meyer-md

Dr Meyer is a voluntary clinical professor of psychiatry at the University of California, San Diego.

Articles

Demystifying Lithium Therapy—A Primer for Clinicians: Lithium-Related Polyuria, Part 2

January 24th 2025

In this CME article, learn more about alternative methods to screen for lithium-related polyuria and how to implement amiloride for lithium-related polyuria.

Demystifying Lithium Therapy—A Primer for Clinicians: Renal Issues, Part 1

Jonathan M. Meyer, MD, DLFAPA

December 20th 2024

In this CME article, learn more about recent developments with lithium as they relate to renal issues.

Questions and Answers About Clozapine, Part 2: A Dialogue About Indications for Clozapine, Managing Adverse Effects, and More

Jonathan M. Meyer, MD, DLFAPA

July 22nd 2024

In this CME article, review management of several clozapine-related adverse effects and outline considerations when addressing inadequate positive symptom response to clozapine.

Questions and Answers About Clozapine: A Dialogue About the Use of Plasma Levels

Jonathan M. Meyer, MD, DLFAPA

June 20th 2024

In this CME article, read more about best practices for utilizing clozapine plasma levels and the clozapine/norclozapine ratio to monitor clozapine therapy.

Lithium Undervalued? A Conversation With Jonathan M. Meyer, MD

Jonathan M. Meyer, MD, DLFAPA;John J. Miller, MD

May 7th 2024

Jonathan M. Meyer, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

Which treatment approaches are the state-of-the-art for helping this patient population?

Appropriate Treatment for Treatment-Resistant Schizophrenia

Jonathan M. Meyer, MD, DLFAPA

July 14th 2022

Which treatment approaches are the state-of-the-art for helping this patient population?

The Metabolic Syndrome and Schizophrenia: Clinical Research Update

Jonathan M. Meyer, MD, DLFAPA

February 1st 2007

The Metabolic Syndrome and Schizophrenia: Clinical Research Update

Glucose Dysregulation

Hua Jin, MD;Jonathan M. Meyer, MD, DLFAPA

March 1st 2003

The atypical antipsychotics have become the treatment of choice for patients with psychotic and other behavioral disorders. However, case reports, retrospective studies and epidemiological data suggest that these medications may be associated with new-onset type 2 diabetes and diabetic ketoacidosis.